T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma

Authors: Alfred L. Garfall, Ehren K. Dancy, Adam D. Cohen, Wei‐Ting Hwang, Joseph A. Fraietta, Megan M. Davis, Bruce L. Levine, Don L. Siegel, Edward A. Stadtmauer, Dan T. Vogl, Adam Waxman, Aaron P. Rapoport, Michael C. Milone, Carl H. June, J. Joseph Melenhorst - Blood Advances 2019 cited by 229

Key points T cells from patients early in myeloma therapy exhibit better fitness for CAR T manufacturing than those from relapsed/refractory patients. CAR T cells may be more effective if manufactured from patients before onset of relapsed/refractory disease.